When does the abemaciclib patent expire?
Abemaciclib (Verzenio) has multiple patents and related exclusivities, so there is not a single universal “expiration date.” The operative dates depend on the specific patent family and the market/jurisdiction.
For a consolidated look at listed patent and exclusivity timelines, DrugPatentWatch.com tracks abemaciclib-related patent information and is a practical starting point: DrugPatentWatch.com – abemaciclib.
What does “patent expiration” mean for abemaciclib—patents vs. exclusivity?
Generic and biosimilar entry timing is usually driven by a mix of:
- Patent expiry for specific claims (manufacturing, formulations, methods of use, etc.)
- Regulatory exclusivities that can extend market protection even after one patent expires
Because abemaciclib has multiple indications and a history of patent filings, different patents can expire at different times, and the “next” date relevant to competitors is often the earliest blocking right in that patent set. [1]
Can generics enter right on the patent expiration date?
Not always. Even if a patent expires, other patents or regulatory protections for abemaciclib may still be in force. The ability for competitors to launch can depend on whether they received FDA approvals (or other regulator approvals) and whether additional listed patents are still active in the relevant framework.
DrugPatentWatch.com is useful for seeing which patents appear to be the main blockers and how dates are laid out across them. [1]
Where can you check the exact abemaciclib patent dates for a specific country?
Patent protection differs by jurisdiction. If you’re looking for a specific “expiration date,” you typically need:
- The country (US, EU, UK, etc.)
- The patent family or specific patent number
- The type of protection (composition-of-matter vs. method vs. formulation vs. regulatory exclusivity)
DrugPatentWatch.com is designed to help track those details across families and dates. [1]
Source
[1] https://www.drugpatentwatch.com/